NMTRQ — 9 Meters Biopharma Share Price
0.000.00%
Last trade - 00:00- $0.00m
- -$1.87m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -375.64% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 12.5 | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
9 Meters Biopharma, Inc. has ceased operations. The Company has filed a voluntary petition for relief under provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the Eastern District of North Carolina.
Directors
- Mark Sirgo NEC (67)
- John Temperato PRE (56)
- Bethany Sensenig CFO (46)
- Sarah Liu OTH
- Michael Constantino IND (58)
- Lorin Johnson IND (69)
- Michael Rice IND (56)
- Samantha Ventimiglia IND
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- November 9th, 2010
- Public Since
- July 8th, 2016
- No. of Shareholders
- 142
- No. of Employees
- 10
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 14,459,690
- Address
- 4509 CREEDMOOR ROAD, SUITE 600, RALEIGH, 27612
- Web
- https://9meters.com/
- Phone
- +1 9192751933
- Auditors
- Mayer Hoffman & McCann P.C.
Upcoming Events for NMTRQ
9 Meters Biopharma Inc Annual Shareholders Meeting
Similar to NMTRQ
1399 Internet Technology Application
Pink Sheets on Nasdaq
3D Pioneer Systems
Pink Sheets on Nasdaq
A1
Pink Sheets on Nasdaq
Absolute Health and Fitness
Pink Sheets on Nasdaq
ACC Aviation Holdings
Pink Sheets on Nasdaq
FAQ
What is the 9 Meters Biopharma share price?
As of Today at 19:00 UTC, shares in 9 Meters Biopharma are trading at $0.00. This share price information is delayed by 15 minutes.
How has the 9 Meters Biopharma share price performed this year?
Shares in 9 Meters Biopharma last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the 9 Meters Biopharma share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for 9 Meters Biopharma?
The overall consensus recommendation for 9 Meters Biopharma is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the 9 Meters Biopharma dividend yield?
9 Meters Biopharma does not currently pay a dividend.
Does 9 Meters Biopharma pay a dividend?
9 Meters Biopharma does not currently pay a dividend.
When does 9 Meters Biopharma next pay dividends?
9 Meters Biopharma does not currently pay a dividend.
How do I buy 9 Meters Biopharma shares?
To buy shares in 9 Meters Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of 9 Meters Biopharma?
As of the previous close price of $0.00, shares in 9 Meters Biopharma had a market capitalisation of $0.00m.
Where are 9 Meters Biopharma shares listed?
Here are the trading details for 9 Meters Biopharma:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NMTRQ
What kind of share is 9 Meters Biopharma?
Based on an overall assessment of its quality, value and momentum 9 Meters Biopharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a 9 Meters Biopharma share price forecast for 2024?
The analyst consensus target price for shares in 9 Meters Biopharma is $0.75. That is 74999900% above the last closing price of $0.00.
Analysts covering 9 Meters Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.07 for the next financial year.
What is the trend in the 9 Meters Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 9 Meters Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -99.92%.
As of the last closing price of $0.00, shares in 9 Meters Biopharma were trading -100% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the 9 Meters Biopharma PE Ratio?
The 9 Meters Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of 9 Meters Biopharma?
9 Meters Biopharma's management team is headed by:
- Mark Sirgo - NEC
- John Temperato - PRE
- Bethany Sensenig - CFO
- Sarah Liu - OTH
- Michael Constantino - IND
- Lorin Johnson - IND
- Michael Rice - IND
- Samantha Ventimiglia - IND